This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome

This study has been completed.
University of Oslo
University of Stavanger
Information provided by (Responsible Party):
Helse Stavanger HF Identifier:
First received: May 20, 2008
Last updated: August 18, 2015
Last verified: August 2015
Fatigue is a prevalent phenomenon in Primary Sjøgrens syndrome (PSS). Observations indicate that the cytokine IL-1 is of importance for this phenomenon. In this study the investigators block IL-1 by giving Anakinra (an IL-1 receptor antagonist) to patients with PSS.

Condition Intervention Phase
Fatigue Primary Sjogren Drug: Anakinra Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Fatigue and IL-1 Blockade in Primary Sjøgrens Syndrome

Resource links provided by NLM:

Further study details as provided by Helse Stavanger HF:

Primary Outcome Measures:
  • Fatigue as measured by Fatigue Severity Scale and a visual analogue fatigue scale [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Inflammatory cytokines and measures of oxidative stress [ Time Frame: 4 weeks ]

Enrollment: 28
Study Start Date: January 2008
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Anakinra
Anakinra self-administered s.c. in a dose of 100mg daily
Drug: Anakinra
Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
Other Name: Kineret
Placebo Comparator: Placebo
Placebo self-adminsitered s.c in a dose 0.67ml daily
Drug: Placebo
Saline 0.67 ml daily subcutaneously as placebo drug.
Other Name: Saline 0.9%

Detailed Description:
A double-blind, placebo-controlled, parallel study of the effect on fatigue of daily injections of Anakinra for one month.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary Sjøgrens Syndrome according to the European-American criteria
  • Age 18-80 years
  • Written informed consent

Exclusion Criteria:

  • Hyper- og hypothyreosis
  • Malignant disease
  • Parkinsons disease
  • Multiple sclerosis
  • Conditions or diseases where Anakinra is contraindicated
  • Mental depression (BDI >13)
  • Neutropenia (<1.5*10.9)
  • Frequent infections
  • Pregnancy, lactating women.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00683345

Stavanger University Hospital
Stavanger, Norway, N-4068
Sponsors and Collaborators
Helse Stavanger HF
University of Oslo
University of Stavanger
Principal Investigator: Roald Omdal, PhD Helse Stavanger HF
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Helse Stavanger HF Identifier: NCT00683345     History of Changes
Other Study ID Numbers: P REK NORD 60/2007
2007-000475-41 ( EudraCT Number )
17772 ( Other Identifier: NSD )
07/03834-7 ( Other Identifier: Norwegian Medicines Agency )
Study First Received: May 20, 2008
Last Updated: August 18, 2015

Additional relevant MeSH terms:
Sjogren's Syndrome
Signs and Symptoms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents processed this record on August 18, 2017